196 related articles for article (PubMed ID: 17448964)
21. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
Schmid C; Labopin M; Nagler A; Bornhäuser M; Finke J; Fassas A; Volin L; Gürman G; Maertens J; Bordigoni P; Holler E; Ehninger G; Polge E; Gorin NC; Kolb HJ; Rocha V;
J Clin Oncol; 2007 Nov; 25(31):4938-45. PubMed ID: 17909197
[TBL] [Abstract][Full Text] [Related]
22. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.
Suttorp M
Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S40-6. PubMed ID: 18978743
[TBL] [Abstract][Full Text] [Related]
23. Expansion of antileukaemia CTL lines and clones for adoptive cell therapy in paediatric patients given allogeneic haematopoietic stem cell transplantation.
Montagna D; Maccario R; Locatelli F
Int J Immunogenet; 2008 Aug; 35(4-5):389-93. PubMed ID: 18976444
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.
Robin M; Porcher R; De Castro Araujo R; de Latour RP; Devergie A; Rocha V; Larghero J; Adès L; Ribaud P; Mary JY; Socié G
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1304-12. PubMed ID: 17950917
[TBL] [Abstract][Full Text] [Related]
26. Cytokine expression in tumors treated with donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
Conrad R; Remberger M; Cederlund K; Barkholt L
Immunotherapy; 2011 Mar; 3(3):443-51. PubMed ID: 21395385
[TBL] [Abstract][Full Text] [Related]
27. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
[TBL] [Abstract][Full Text] [Related]
28. Donor lymphocyte infusions: the long and winding road: how should it be traveled?
Tomblyn M; Lazarus HM
Bone Marrow Transplant; 2008 Nov; 42(9):569-79. PubMed ID: 18711351
[TBL] [Abstract][Full Text] [Related]
29. Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose.
Fozza C; Szydlo RM; Abdel-Rehim MM; Nadal E; Goldman JM; Apperley JF; Dazzi F
Br J Haematol; 2007 Mar; 136(6):833-6. PubMed ID: 17341269
[TBL] [Abstract][Full Text] [Related]
30. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population.
Levine JE; Barrett AJ; Zhang MJ; Arora M; Pulsipher MA; Bunin N; Fort J; Loberiza F; Porter D; Giralt S; Drobyski W; Wang D; Pavletic S; Ringden O; Horowitz MM; Collins R
Bone Marrow Transplant; 2008 Aug; 42(3):201-5. PubMed ID: 18490913
[TBL] [Abstract][Full Text] [Related]
31. Donor leukocyte infusions in myeloid malignancies: new strategies.
Porter DL; Antin JH
Best Pract Res Clin Haematol; 2006; 19(4):737-55. PubMed ID: 16997180
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment of relapsed CML after cord blood transplantation with donor leukocyte infusion IL-2 and IFNalpha.
Laws HJ; Nürnberger W; Körholz D; Kögler G; Fischer J; Niehues T; Wernet P; Göbel U
Bone Marrow Transplant; 2000 Jan; 25(2):219-22. PubMed ID: 10673686
[TBL] [Abstract][Full Text] [Related]
33. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.
Giralt SA; Arora M; Goldman JM; Lee SJ; Maziarz RT; McCarthy PL; Sobocinski KA; Horowitz MM;
Br J Haematol; 2007 Jun; 137(5):461-7. PubMed ID: 17459051
[TBL] [Abstract][Full Text] [Related]
34. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
[TBL] [Abstract][Full Text] [Related]
35. Donor lymphocyte infusions for acute myeloid leukaemia.
Soiffer RJ
Best Pract Res Clin Haematol; 2008 Sep; 21(3):455-66. PubMed ID: 18790449
[TBL] [Abstract][Full Text] [Related]
36. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
37. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
Valcárcel D; Martino R
Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
[TBL] [Abstract][Full Text] [Related]
38. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.
Roddie C; Peggs KS
Expert Opin Biol Ther; 2011 Apr; 11(4):473-87. PubMed ID: 21269237
[TBL] [Abstract][Full Text] [Related]
39. Risk assessment in haematopoietic stem cell transplantation: impact of donor-recipient sex combination in allogeneic transplantation.
Gahrton G
Best Pract Res Clin Haematol; 2007 Jun; 20(2):219-29. PubMed ID: 17448958
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007.
Goldman J
Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S11-S13. PubMed ID: 18724281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
